A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19.pdf (856.17 kB)
Download file

A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19

Download (856.17 kB)
journal contribution
posted on 07.03.2022, 15:10 authored by Oliver McElvaneyOliver McElvaney, Brian D Hobbs, Dandi Qiao, Oisin McelvaneyOisin Mcelvaney, Matthew Moll, Natalie McEvoyNatalie McEvoy, Jennifer ClarkeJennifer Clarke, Eoin O’Connor, Seán Walsh, Michael H Cho, Gerard CurleyGerard Curley, Noel G McElvaneyNoel G McElvaney

Background: Prognostic tools are required to guide clinical decision-making in COVID-19.

Methods: We studied the relationship between the ratio of interleukin (IL)-6 to IL-10 and clinical outcome in 80 patients hospitalized for COVID-19, and created a simple 5-point linear score predictor of clinical outcome, the Dublin-Boston score. Clinical outcome was analysed as a three-level ordinal variable ("Improved", "Unchanged", or "Declined"). For both IL-6:IL-10 ratio and IL-6 alone, we associated clinical outcome with a) baseline biomarker levels, b) change in biomarker level from day 0 to day 2, c) change in biomarker from day 0 to day 4, and d) slope of biomarker change throughout the study. The associations between ordinal clinical outcome and each of the different predictors were performed with proportional odds logistic regression. Associations were run both "unadjusted" and adjusted for age and sex. Nested cross-validation was used to identify the model for incorporation into the Dublin-Boston score.

Findings: The 4-day change in IL-6:IL-10 ratio was chosen to derive the Dublin-Boston score. Each 1 point increase in the score was associated with a 5.6 times increased odds for a more severe outcome (OR 5.62, 95% CI -3.22-9.81, P = 1.2 × 10-9). Both the Dublin-Boston score and the 4-day change in IL-6:IL-10 significantly outperformed IL-6 alone in predicting clinical outcome at day 7.

Interpretation: The Dublin-Boston score is easily calculated and can be applied to a spectrum of hospitalized COVID-19 patients. More informed prognosis could help determine when to escalate care, institute or remove mechanical ventilation, or drive considerations for therapies.

Funding

American Thoracic Society International Trainee Scholarship

Parker B Francis Research Opportunity Award

Elaine Galwey Research Fellowship

National Institutes of Health K08 HL136928; R01 HL089856; T32 HL00742; K01 HL129039; R01 HL135142; R01 HL089856

History

Comments

The original article is available at https://www.thelancet.com/ This article has an corrigendum that can be found at https://doi.org/10.1016/j.ebiom.2020.103116. McElvaney OJ. et al. Corrigendum to 'A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19'. EBioMedicine. 2020;62:103116

Published Citation

McElvaney OJ. et al. A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine. 2020;61:103026

Publication Date

8 October 2020

PubMed ID

33039714

Department/Unit

  • Anaesthetics and Critical Care
  • Beaumont Hospital
  • Medicine

Publisher

Elsevier B.V

Version

  • Published Version (Version of Record)